Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Co-Principal Investigator
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Principal Investigator
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Co-Principal Investigator
Overview
researcher role of
Li, Yan
contributes to
Novel drug VS-105 for treatment of diabetic nephropathy